Advaxis to Report 12-Month Survival from Its Phase 2 Study of ADXS-HPV in Women with Recurrent/Refractory Cervical Cancer
Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor Relations & Business Development
Advaxis, Inc., (OTCBB: ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company’s lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.
Abstract #5529, titled , was selected for presentation at the Poster Discussion Session: Gynecologic Cancer to be held on June 2, 2013 from 8:00 – 11:30 a.m. This poster will describe updated safety, tumor response, and survival data from the ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin being conducted by Advaxis in India.
Abstract #TPS3121, titled was selected for presentation at the Developmental Therapeutics – ImmunotherapyTrials in Progress General Poster Session to be held on June 3, 2013 from 8:00 -11:45 a.m. This poster will describe the trial design for the ongoing Phase 2 study being conducted by the Gynecologic Oncology Group (GOG) in the United States.
Abstracts will be released on at 6:00 PM on May 15, 2013.
“We are pleased to have the opportunity to present the final 12-month survival and other relevant data from our 110 patient trial of ADXS-HPV in recurrent/refractory cervical cancer at ASCO’s annual meeting,” commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis. “ADXS-HPV immunotherapy offers the promise of an effective and well-tolerated treatment for cervical cancer that employs the patient’s immune system to fight the cancer. We are encouraged by the interest that our colleagues in GOG have in joining our efforts to evaluate the potential of ADXS-HPV in cervical cancer, through the conduct of GOG-0265.”
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.
In April 2012, Advaxis’ clinical stage product candidate, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.
ADXS-HPV is currently being evaluated in 5 clinical trials for human papillomavirus, or HPV, associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (U.S. study, Clinical Trials.gov Identifier NCT01116245), head & neckcancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, Brown University Oncology Group, and others. For more information please visit: | |